Corrigendum to “Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: Results from the 1958 British Birth Cohort Study” [Pain 149 (2010) 143–151]

Ò

PAIN 150 (2010) 210

www.elsevier.com/locate/pain

Corrigendum

Corrigendum to ‘‘Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: Results from the 1958 British Birth Cohort Study” [Pain 149 (2010) 143–151] Lynne J. Hocking a,*, Blair H. Smith b, Gareth T. Jones c, David M. Reid a, David P. Strachan d, Gary J. Macfarlane c a

Aberdeen Pain Research Collaboration (Bone and Musculoskeletal Research Programme), Division of Applied Medicine, School of Medicine and Dentistry University of Aberdeen, UK Aberdeen Pain Research Collaboration (Primary Care), Division of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen, UK c Aberdeen Pain Research Collaboration (Epidemiology Group), Division of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen, UK d Division of Community Health Sciences, St. George’s, University of London, UK b

It has been brought to our attention that alleles for SNP rs1042714 have been named from the reverse strand rather than the forward strand (as for other SNPs). For clarification, the correct ADRB2 haplotypes have been printed below, with changes from the published manuscript underlined. In 3.2. Genetic variation in ADRB2 and COMT (p146), ‘‘Four ADRB2 haplotypes with frequency above 1% were observed that accounted for 98.9% all haplotypes (GGCC 44.7%; GGGC 17.0%; GGGT 1.5%; AAGC 35.7%)” should read: ‘‘Four ADRB2 haplotypes with frequency above 1% were observed that accounted for 98.9% all haplotypes (GGGC 44.7%; GGCC 17.0%; GGCT 1.5%; AACC 35.7%)”. Table 2 (p147) should be similarly amended as follows:

Table 2 ADRB2 4-SNP model haplotype combinations, and effects on chronic pain. Haplotype ID

Haplotype 1

Haplotype 2

OR (95% CI)

p-Value

pOR (95% CI)

p-Value

H1–H1

G-G-G-C

G-G-G-C

1.20 (0.91–1.59)

0.2

1.09 (0.93–1.28)

0.3

H1–H2

G-G-G-C

G-G-C-C

1.42 (1.06–1.91)

0.02

1.24 (1.05–1.46)

0.01

H1–H4

G-G-G-C

A-A-C-C

1.39 (1.08–1.80)

0.01

1.24 (1.08–1.43)

0.003

H2–H2

G-G-C-C

G-G-C-C

1.83 (1.14–2.92)

0.01

1.58 (1.20–2.07)

0.001

H2–H4

G-G-C-C

A-A-C-C

1.19 (0.87–1.63)

0.3

1.07 (0.89–1.27)

0.5

H4–H4

A-A-C-C Mixed

A-A-C-C Mixed

Ref

–

Ref

–

ND

ND

ND

ND

Other

CWP v control

Pain Status

DOI of original article: 10.1016/j.pain.2010.01.023 * Corresponding author. Address: Bone & Musculoskeletal Research Programme, Division of Applied Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, UK. Tel.: +44 1224 552923; fax: +44 1224 559533. E-mail address: [email protected] (L.J. Hocking). URL: http://wvvw.abdn.ac.uk/ims/staff/details.php?id=l.hocking (L.J. Hocking). 0304-3959/$36.00 Ó 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.pain.2010.04.028